Northwest Biotherapeutics, Inc. (NWBO)

Market Cap	288.08M -24.6%
Revenue (ttm)	2.17M +98.6%
Net Income	-38.88M
EPS	-0.02
Shares Out	1.71B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	575,354
Open	0.1701
Previous Close	0.1683
Day's Range	0.1614 - 0.1723
52-Week Range	0.1411 - 0.3389
Beta	-0.61
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was fou...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 105
• Stock Exchange: OTCMKTS
• Ticker Symbol: NWBO

Financial Performance

In 2025, Northwest Biotherapeutics's revenue was $1.38 million, a decrease of -0.29% compared to the previous year's $1.38 million. Losses were -$61.48 million, -27.84% less than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 14, 2026

Data Sources Report a data error